转移性去势敏感性前列腺癌的一线全身治疗方案:活系统评价与网络Meta分析
该活系统评价与网络Meta分析纳入10项3期随机临床试验、共11043例转移性去势敏感性前列腺癌患者,比较一线全身治疗方案。总体人群中,达罗他胺三联方案(HR 0.68;95%CI 0.57-0.81)和阿比特龙三联方案(HR 0.75;95%CI 0.59-0.95)较多西他赛双联方案改善总生存,但未优于雄激素通路抑制剂双联方案;高瘤负荷患者中阿比特龙三联方案可能改善总生存(HR 0.72;95%CI 0.55-0.95),但未优于阿比特龙+ADT、恩扎卢胺+ADT和Apalutamide+ADT;低瘤负荷患者中阿比特龙三联方案可能未改善总生存。
要点
- 总体人群中达罗他胺三联方案较D+ADT改善OS(HR 0.68;95%CI 0.57-0.81)。
- 总体人群中阿比特龙三联方案较D+ADT改善OS(HR 0.75;95%CI 0.59-0.95)。
- 三联方案与API双联方案的比较存在临床均势,需结合瘤负荷解读。
核心结论
- 三联治疗的潜在获益须结合疾病瘤负荷和临床试验所选双联比较方案谨慎解读。
- 现有证据提示三联方案与API双联方案比较存在临床均势,为未来临床试验提供方向。
研究设计与样本
- 活系统评价与网络Meta分析,检索Ovid MEDLINE(1946年起)和Embase(1974年起)至2021年6月16日,并建立每周更新的活自动检索。
- 纳入10项评估mCSPC一线治疗方案的3期随机临床试验,共11043例患者、9个独特治疗组,采用固定效应网络Meta分析,数据分析于2022年7月10日进行。
- 纳入人群中位年龄范围为63至70岁。
主要发现
- 总体人群中,达罗他胺三联方案(DARO+D+ADT)较D+ADT改善OS(HR 0.68;95%CI 0.57-0.81),但未优于API双联方案。
- 总体人群中,阿比特龙三联方案(AAP+D+ADT)较D+ADT改善OS(HR 0.75;95%CI 0.59-0.95),但未优于API双联方案。
- 高瘤负荷患者中,AAP+D+ADT较D+ADT可能改善OS(HR 0.72;95%CI 0.55-0.95),但未优于AAP+ADT、恩扎卢胺+ADT和Apalutamide+ADT。
- 低瘤负荷患者中,AAP+D+ADT较Apalutamide+ADT、AAP+ADT、恩扎卢胺+ADT和D+ADT可能未改善OS。
关键数值与推荐
- 总体人群:DARO+D+ADT vs D+ADT的OS HR 0.68(95%CI 0.57-0.81)。
- 总体人群:AAP+D+ADT vs D+ADT的OS HR 0.75(95%CI 0.59-0.95)。
- 高瘤负荷患者:AAP+D+ADT vs D+ADT的OS HR 0.72(95%CI 0.55-0.95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effectiveness of triplet therapy compared with androgen pathway inhibitor (API) doublets in a heterogeneous patient population with metastatic castration-sensitive prostate cancer (mCSPC) is unknown. OBJECTIVE: To assess the comparative effectiveness of contemporary systemic treatment options for patients with mCSPC across clinically relevant subgroups. DATA SOURCES: For this systematic review and meta-analysis, Ovid MEDLINE and Embase were searched from each database's inception (MEDLINE, 1946; Embase, 1974) through June 16, 2021. Subsequently, a "living" auto search was created with weekly updates to identify new evidence as it became available. STUDY SELECTION: Phase 3 randomized clinical trials (RCTs) assessing first-line treatment options for mCSPC. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers extracted data from eligible RCTs. The comparative effectiveness of different treatment options was assessed with a fixed-effect network meta-analysis. Data were analyzed on July 10, 2022. MAIN OUTCOMES AND MEASURES: Outcomes of interest included overall survival (OS), progression-free survival (PFS), grade 3 or higher adverse events, and health-related quality of life. RESULTS: This report included 10 RCTs with 11 043 patients and 9 unique treatment groups. Median ages of the included population ranged from 63 to 70 years. Current evidence for the overall population suggests that the darolutamide (DARO) triplet (DARO + docetaxel [D] + androgen deprivation therapy [ADT]; hazard ratio [HR], 0.68; 95% CI, 0.57-0.81), as well as the abiraterone (AAP) triplet (AAP + D + ADT; HR, 0.75; 95% CI, 0.59-0.95), are associated with improved OS compared with D doublet (D + ADT) but not compared with API doublets. Among patients with high-volume disease, AAP + D + ADT may improve OS compared with D + ADT (HR, 0.72; 95% CI, 0.55-0.95) but not compared with AAP + ADT, enzalutamide (E) + ADT, and apalutamide (APA) + ADT. For patients with low-volume disease, AAP + D + ADT may not improve OS compared with APA + ADT, AAP + ADT, E + ADT, and D + ADT. CONCLUSIONS AND RELEVANCE: The potential benefit observed with triplet therapy must be interpreted with careful accounting for the volume of disease and the choice of doublet comparisons used in the clinical trials. These findings suggest an equipoise to how triplet regimens compare with API doublet combinations and provide direction for future clinical trials.
引用
- Riaz IB, Naqvi SAA, He H, et al. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. JAMA Oncol. 2023. PMID: 36862387. doi:10.1001/jamaoncol.2022.7762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。